AstraZeneca

The chance of developing cerebral venous sinus thrombosis was nearly 10 times higher in the two weeks following a diagnosis of SARS-CoV-2 infection than after receiving an mRNA vaccine, a data analysis finds.

The FDA and CDC are investigating a handful of reports of blood clots that occurred several days after people received the one-and-done shot.

The European Medicines Agency emphasizes that the benefits of the jab in protecting against COVID-19 still far outweigh the risks.

The vaccine was 79 percent effective at blocking symptomatic infections, according to data from a Phase 3 trial in the US, Chile, and Peru. A US safety oversight board says the data might be incomplete.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

Rollouts of the shot have ground to a halt following reports of blood clots, but health authorities say that these fears are unfounded and vaccination programs should continue.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

Two preliminary reports from the UK provide real-world evidence in support of the Pfizer/BioNTech and Oxford-AstraZeneca vaccines.

The hold will likely delay trial results, and scientists say the pause is proof that safety protocols in clinical trials are working as they should.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

Positions for 1,600 scientists at the pharmaceutical company will be eliminated globally.